Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials-Reference-Cited by-同舟云学术

Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials

Published:2022-07-03 Issue:3 Volume:14 Page:270-282
ISSN:1946-6315
Container-title:Statistics in Biopharmaceutical Research
language:en
Short-container-title:Statistics in Biopharmaceutical Research

Author:

Liu Rong¹,Yuan Ying²,Sen Suman³,Yang Xin³,Jiang Qi⁴,Li Xiaoyun (Nicole)⁵,Lu Chengxing (Cindy)⁶,Gönen Mithat⁷,Tian Hong⁵,Zhou Heng⁸,Lin Ruitao²^ORCID,Marchenko Olga⁹

Affiliation:

1. Bristol-Myers Squibb, Berkeley Heights, NJ;

2. The University of Texas MD Anderson Cancer Center, Houston, TX;

3. Novartis Pharmaceuticals Corp., East Hanover, NJ;

4. Seagen;

5. BeiGene, San Mateo, CA;

6. AstraZeneca, Waltham, MA;

7. Memorial Sloan Kettering Cancer Center, New York, NY;

8. Merck & Co., Inc, Kenilworth, NJ;

9. Bayer, Whippany, NJ

Funder

Ying Yuan’s research

National Cancer Institute.

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/19466315.2022.2081602

Reference51 articles.

1. A simulation‐free approach to assessing the performance of the continual reassessment method

2. A Generalized Continual Reassessment Method for Two-Agent Phase I Trials

3. A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents

4. A Bayesian dose finding design for oncology clinical trials of combinational biological agents

5. Designs for Single- or Multiple-Agent Phase I Trials

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comb-BOIN12: A Utility-Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination Trials;Statistics in Biopharmaceutical Research;2024-08-28

2. Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective;Statistics in Biopharmaceutical Research;2024-05-14

3. DOD-Combo: Bayesian dose finding design in combination trials with meta-analytic-predictive prior;Journal of Biopharmaceutical Statistics;2024-03-11